ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last81 to 100 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
5ARI Users vs Non 5ARI Users: Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts, and Ontario Regional Mental Health Database)38 of 93,197

36 of 93,197

0.0 points

-0.0 to 0.0

186,394NCT02876757

5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

5ARI Users vs Non 5ARI Users: deaths from any cause160 of 93,197

139 of 93,197

0.0 points

-0.0 to 0.1

186,394NCT02876757

5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

5ARI Users vs Non 5ARI Users: Suicide Attempt (Based on Administrative Data Elements From National Ambulatory Care Reporting System, and Ontario Regional Mental Health Database)169 of 93,197

130 of 93,197

0.0 points

0.0 to 0.1

186,394NCT02876757

5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

5ARI Users vs Non 5ARI Users: Depression (Based on Administrative Data Elements From Hospital Discharge Abstract Database, and Ontario Regional Mental Health Database and Ontario Health Insurance Plan)1,750 of 89,844

1,231 of 89,844

0.6 points

0.5 to 0.7

179,688NCT02876757

5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

Cases vs Controls: Number of Participants Aged 45-64 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person639 of 33,497

1,858 of 133,987

0.5 points

0.4 to 0.7

167,484NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Cases vs Controls: Number of Participants Aged ≥65 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person1,434 of 33,225

4,113 of 132,776

1.2 points

1.0 to 1.5

166,001NCT04969653

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Maternal Referral, Before or After Delivery5,381 of 81,925

4,779 of 79,182

0.5 points

0.3 to 0.8

161,107NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Newborn Referral1,455 of 81,925

1,186 of 79,182

0.3 points

0.2 to 0.4

161,107NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Cesarean Section1,469 of 80,922

1,330 of 78,120

0.1 points

-0.0 to 0.2

159,042NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Stillbirth1,513 of 80,061

1,559 of 77,454

-0.1 points

-0.3 to 0.0

157,515NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Perinatal Death Within 7 Days3,839 of 79,790

3,606 of 77,338

0.1 points

-0.1 to 0.4

157,128NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Hysterectomy Within 7 Days19 of 79,705

18 of 77,252

0.0 points

-0.0 to 0.0

156,957NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Participants With Blood Transfusion Within 7 Days640 of 79,697

625 of 77,254

-0.0 points

-0.1 to 0.1

156,951NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Intervention Health Facility Participants vs Control Health Facility Participants: Count of Mothers Returning to Facility for a Health Problem Within 7 Days2,014 of 79,655

2,141 of 77,220

-0.2 points

-0.4 to -0.1

156,875NCT02148952

BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program

Lung Screening vs Control: Lung Cancer Deaths1,213 of 77,445

1,230 of 77,456

-0.0 points

-0.1 to 0.1

154,901NCT01696968

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

Lung Screening vs Control: Lung Cancer Incidence1,696 of 77,445

1,620 of 77,456

0.1 points

-0.0 to 0.2

154,901NCT01696968

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

Lung Screening vs Control: Deaths From All Causes10,827 of 77,445

11,061 of 77,456

-0.3 points

-0.6 to 0.0

154,901NCT01696968

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

Colorectal Screening vs Control: Colorectal Cancer Incidence1,012 of 77,445

1,287 of 77,455

-0.4 points

-0.5 to -0.2

154,900NCT01696981

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Colorectal Screening vs Control: Deaths From All Causes10,835 of 77,445

11,064 of 77,455

-0.3 points

-0.6 to 0.1

154,900NCT01696981

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Colorectal Screening vs Control: Colorectal Cancer Deaths252 of 77,445

341 of 77,455

-0.1 points

-0.2 to -0.1

154,900NCT01696981

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=5

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02876757-a3ff0393",
        "title": "5ARI Users vs Non 5ARI Users: Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts, and Ontario Regional Mental Health Database)",
        "summary": "38 of 93197 against 36 of 93197; risk difference 0.0 points, 95% interval -0.0 to 0.0; NCT02876757, 5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression",
        "record": "/library/comparisons/NCT02876757-a3ff0393",
        "nct_id": "NCT02876757",
        "kind": "outcome",
        "participants": 186394,
        "risk_difference": {
          "value": 0.000021459918237711547,
          "lower": -0.00016366130674339946,
          "upper": 0.00020733731427011735
        },
        "group_1": "38 of 93,197",
        "group_2": "36 of 93,197",
        "difference": "0.0 points",
        "interval": "-0.0 to 0.0",
        "trial_title": "5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression"
      },
      {
        "id": "NCT02876757-deaths",
        "title": "5ARI Users vs Non 5ARI Users: deaths from any cause",
        "summary": "160 of 93197 against 139 of 93197; risk difference 0.0 points, 95% interval -0.0 to 0.1; NCT02876757, 5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression",
        "record": "/library/comparisons/NCT02876757-deaths",
        "nct_id": "NCT02876757",
        "kind": "deaths",
        "participants": 186394,
        "risk_difference": {
          "value": 0.000225329141495971,
          "lower": -0.00013932970681645535,
          "upper": 0.0005919938487861452
        },
        "group_1": "160 of 93,197",
        "group_2": "139 of 93,197",
        "difference": "0.0 points",
        "interval": "-0.0 to 0.1",
        "trial_title": "5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=6",
  "request_id": "xJiGOSw3tNZZ4Zlp"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?